Clinical Trials · NCT01359488
VRS-317 in Adult Subjects With Growth Hormone Deficiency
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Versartis Inc.
- Enrollment
- 50
- Start date
- Mar 2011
- Locations
- 1 site, United States
- Primary endpoint
- Safety and Tolerability of single dose of VRS-317